Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Pfs230D1-ferritin
- Development stage
- Preclinical
- Lead developer
- National Institute of Allergy and Infectious Diseases
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes, Nanoparticles → Drug Delivery Systems
- Administration
- Intramuscular
01
Overview
Pfs230D1-ferritin is a single-component, self-assembling 24-copy nanoparticle vaccine designed to block the transmission of *Plasmodium falciparum* malaria. Developed by the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH), the vaccine consists of Domain 1 of the *P. falciparum* gametocyte surface protein Pfs230 (Pfs230D1) genetically fused to *Helicobacter pylori* ferritin. This fusion allows the self-assembly of stable, homogenous nanoparticles that present potent transmission-blocking conformational epitopes of Pfs230D1. By eliciting antibodies that target Pfs230, the vaccine aims to disrupt the fertilization and development of the malaria parasite within the mosquito midgut after the vector feeds on an infected human host, thereby breaking the cycle of transmission.
- Other names
- Pfs230D1-ferritin nanoparticle vaccinePfs-230D1-ferritin nanoparticle vaccinePfs 230D1-ferritin nanoparticle vaccinePfs230D1-ferritin vaccinePfs-230D1-ferritin vaccinePfs 230D1-ferritin vaccine
02
Targets
Pfs230
Beyond the preview
Go deeper on Pfs230D1-ferritin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Pfs230D1-ferritin.